News stories about Neovasc (NASDAQ:NVCN) (TSE:NVC) have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neovasc earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 46.1688598854181 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Separately, Zacks Investment Research downgraded shares of Neovasc from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th.

Shares of Neovasc (NASDAQ:NVCN) traded down 1.34% during mid-day trading on Tuesday, reaching $1.47. 35,794 shares of the company’s stock traded hands. Neovasc has a 12-month low of $0.46 and a 12-month high of $3.34. The stock’s market capitalization is $116.00 million. The company’s 50-day moving average price is $1.55 and its 200-day moving average price is $1.39.

Neovasc (NASDAQ:NVCN) (TSE:NVC) last posted its quarterly earnings results on Thursday, August 10th. The medical equipment provider reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). Neovasc had a negative net margin of 68.34% and a negative return on equity of 58.08%. The firm had revenue of $1.31 million during the quarter, compared to analysts’ expectations of $1.40 million. Analysts anticipate that Neovasc will post ($0.34) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Neovasc (NVCN) Share Price” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at

Neovasc Company Profile

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.

Insider Buying and Selling by Quarter for Neovasc (NASDAQ:NVCN)

Receive News & Ratings for Neovasc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.